CS274177B1 - 2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation - Google Patents
2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation Download PDFInfo
- Publication number
- CS274177B1 CS274177B1 CS150288A CS150288A CS274177B1 CS 274177 B1 CS274177 B1 CS 274177B1 CS 150288 A CS150288 A CS 150288A CS 150288 A CS150288 A CS 150288A CS 274177 B1 CS274177 B1 CS 274177B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- trans
- acid
- amino
- hydroxymethyl
- oxo
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 241000233866 Fungi Species 0.000 claims abstract description 8
- 241000795305 Melanconiella flavovirens Species 0.000 claims abstract description 3
- 239000002028 Biomass Substances 0.000 claims abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 235000021309 simple sugar Nutrition 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XWLAEUYYVDDBEK-FMIVXFBMSA-N flavovirin Chemical compound CCCCCCC(=O)CCCCCC\C=C\CC1OC1C(N)(CO)C(O)=O XWLAEUYYVDDBEK-FMIVXFBMSA-N 0.000 description 21
- WYHZRRKOWQBAFU-UHFFFAOYSA-N Flavovirin Natural products CCCCCCC(=O)CCCCCCC=C/C1OC1C(N)(CO)C(=O)O WYHZRRKOWQBAFU-UHFFFAOYSA-N 0.000 description 20
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 17
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 241000521553 Pichia fermentans Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001515917 Chaetomium globosum Species 0.000 description 1
- 241000177202 Chimonobambusa utilis Species 0.000 description 1
- 241000324121 Cytospora leucostoma Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001123674 Metschnikowia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000800402 Myriococcum Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001136489 Talaromyces stipitatus Species 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- JSCQSBGXKRTPHZ-SYKZHUKTSA-N mucidin Chemical compound CO\C=C(\C(=O)OC)/C(/C)=C\C=C\C1=CC=CC=C1 JSCQSBGXKRTPHZ-SYKZHUKTSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Vynález ee týká kyseliny 2-amino-2-hydroxymathyl-3,4-trans-apoxy-14-oxo-trans-eikosanové a způsobu jeji připravy.The invention relates to 2-amino-2-hydroxymethyl-3,4-trans-apoxy-14-oxo-trans-eicosanoic acid and to a process for its preparation.
Dále je předmětem vynálezu použiti této látky jako antibiotika. Kyselina aa vyznačuje vysokou antibiotickou účinnosti proti kvasinkám a vláknitým houbám.It is a further object of the invention to use the compound as an antibiotic. Acid aa is characterized by high antibiotic activity against yeast and filamentous fungi.
□a znám calkam malý počat antibiotik a syntetických preparátů užívaných v terapii mykotických onemocněni člověka. Vzhledem k současnému vzrůstajícímu počtu těchto onemocněni a stoupající rezistenci původců onemocněni proti užívaným preparátům je trvalá potřeba hledat dalši látky, které máji antifungální účinek.Znám and I know a small number of antibiotics and synthetic preparations used in the treatment of mycotic diseases in humans. Due to the current increasing number of these diseases and the increasing resistance of pathogens to the drugs used, there is a continuing need to look for other substances that have an antifungal effect.
Z používaných antifungálnich antibiotik lze uvést zejména antibiotika polyénového typu produkovaná straptomycaty, nako např. nystatin (Házen E. L. a Brown R., Science 112: 423, 1950), amfotaricin B (Gold W. a kol., Antibiotlcs Ann.: 579, 1955/1956) nabo primaricin (Struyk A, P. a kol., Antibiotlcs Ann.: 878, 1957/1958) dála griaaofulvin produkovaný kulturou Panicilllum grieaofulvum (Oxford A, F. a kol., Biocham. □, 33: 240, 1939) a konečně i československý mucidln (Mucidermin SPOFA) produkovaný kulturou Oudamansialla mucida (Čs. pat. 136 492).Among the antifungal antibiotics used are, in particular, polyene-type antibiotics produced by straptomycates, such as nystatin (Házen EL and Brown R., Science 112: 423, 1950), amphotaricin B (Gold W. et al., Antibiotics Ann .: 579, 1955). (1956) or primaricin (Struyk A, P. et al., Antibiotlcs Ann .: 878, 1957/1958) of griaaofulvin produced by Panicilllum grieaofulvum culture (Oxford A, F. et al., Biocham., 33: 240, 1939) ) and finally the Czechoslovak mucidine (Mucidermin SPOFA) produced by the culture of Oudamansialla mucida (Cs. pat. 136 492).
K léčbě mykotických onemocněni sa vadla antibiotik používají i eyntaticky připravená antimykotika, z nichž se v posledních letech zjaména uplatňuji imidazolové sloučeniny.Eyntatically prepared antifungal agents have also been used to treat fungal diseases, including imidazole compounds in recent years.
Nevýhodou některých těchto známých látek ja, ža například řada z nich není účinná proti kvasinkám nabo jejich specifická účinnost je malá.A disadvantage of some of these known substances is that, for example, many of them are not effective against yeast or their specific activity is low.
Tyto nevýhody odstraňuje kyselina 2-amino-2-hydroxymathyl-3,4-trans-apoxy-14-oxo-6-trans-aikosanová obecného vzorcaThese drawbacks are overcome by 2-amino-2-hydroxymethyl-3,4-trans-apoxy-14-oxo-6-trans-aicosanoic acid of the general formula
O /\O / \
NH,NH,
CH3-(CH2)5-C0-(CH2)6-CH»CH-CH2-CH-CH-C-C00H \CH 3 - (CH 2 ) 5 -CO- (CH 2 ) 6 -CH 2 CH-CH 2 -CH-CH-C-COOH
CH20H u které byla zjištěna vysoká antibiotická účinnost proti kvasinkám a vláknitým houbám.CH 2 OH which has been found to be highly antibiotic against yeasts and filamentous fungi.
Z tohoto důvodu lza tuto kyselinu použit jako účinné antibiotikum.For this reason, this acid can be used as an effective antibiotic.
Kyselina 2-amino-2-hydroxymathyl-3,4-trana-apoxy-oxo-6-tran8-aikosanová sa připravuje tak, ža sa aerobně kultivuje houba Malanconia flavovirana na tekuté živná půdě obsahující jednoduché cukry nebo polysacharidy v koncentraci 1 až 10 % hmot. jako zdroj uhlíku a komplexní zdroj dusíku a to při teplotě v rozmázl 18 až 30 °C, pH v rozmázl 4,0 až2-Amino-2-hydroxymethyl-3,4-trana-apoxy-oxo-6-tran8-aicosanoic acid is prepared by aerobically cultivating the fungus Malanconia flavovirana on a liquid medium containing simple sugars or polysaccharides at a concentration of 1 to 10% wt. as a carbon source and a complex nitrogen source at temperatures ranging from 18 to 30 ° C, pH ranging from 4.0 to
6,5.6.5.
Výhodné ja provádět kultivaci 3ubmarznim způsobem, Jako produkční organismus sa může použit například kmen houby Malanconis flavovirana uložený va ablrca CCF pod č. 1 886, Uvedená kyselina podlá vynálezu sa vyznačuje antifungální účinnosti zejména proti kvasinkám a vláknitým houbám.As a production organism, for example, a strain of Malanconis flavovirana deposited in ablrca CCF under No. 1,886 can be used. The acid according to the invention has antifungal activity, in particular against yeasts and filamentous fungi.
Podrobná charakteristika nového antibiotikaDetailed characteristics of the new antibiotic
Kyselina 2-amino-2-hydroxymathyl-3,4-trans-apoxy-14-oxo-6-trana-aikosanová (dála jen pracovní název flavovirin) ja bilá krystalická sloučenina 8 následujícími vlastnostmi: teplota táni 156 až 158 °C, optická otáčivost + 13,5° _+ 1° (c O, 66 % pyr.), UV spektrum namá žádné charakteristická maximum, IČ spektrum (KBr) má významná maxima při 3 415,2-Amino-2-hydroxymethyl-3,4-trans-apoxy-14-oxo-6-trancaicosanoic acid (hereinafter referred to as flavovirin) is a white crystalline compound having the following properties: mp 156-158 ° C, optical Rotation +13.5 ° + 1 ° (c0.66% pyr.), UV spectrum has no characteristic maximum, IR spectrum (KBr) has significant peaks at 3,415,
926, 2 854, 1709, 1 645, 1 499, 1 457, 1 254, 1 064, 972, 908 cml. Viz obr. lj 1H NMR 13 spektrum, viz obr. 2j C NMR spektrum, viz tabulka 1. Elementární analýza: pro sumární vzorec C2lH37N05 (m. h. 383) vypočteno: C 65,77 %, H 9,72 %, N 3,65 %j nalezeno: C 65,67 %, H 9,65 %, N 3,72 %. Pozitivní reakce: a ninhydrinem a dinitrofanylhydrazinam. Rozpustnost: flavovirin ja nerozpustný v patrolsthsru, disthylathsru, benzenu, částečně rozpustCS 274 177 Bl ný v chloroformu, methanolu, ethanolu, n-butanolu, dimethylformamidu, dimethylsulfoxidu, pyridinu.926, 2,854, 1709, 1,645, 1,499, 1,457, 1,254, 1,064, 972, 908 cm -1. See Fig. Lj 1 H NMR spectrum of 13, see Fig. 2, C NMR, see Table 1. Elemental analysis for molecular formula C 37 H N0 2 l 5 (MH 383) calculated: C 65.77%, H 9.72 %, N 3.65% found: C 65.67%, H 9.65%, N 3.72%. Positive reactions: and ninhydrin and dinitropanylhydrazinam. Solubility: flavovirin is insoluble in patrolstyr, disthylathr, benzene, partially soluble in chloroform, methanol, ethanol, n-butanol, dimethylformamide, dimethylsulfoxide, pyridine.
Stabilita: sloučenina Je v roztoku v rozsahu pH 2 až 10 stabilní, při zahříváni na 100 °C po 15 min. klesá Jeji aktivita na polovinu, při skladováni při teplotě 4 °C se aktivita antibiotika během několka měsíců nezměnila.Stability: the compound is stable in solution over a pH range of 2 to 10 when heated to 100 ° C for 15 min. Its activity is halved, when stored at 4 ° C the antibiotic activity has not changed over several months.
Antibiotická účinnost je výrazná proti kvasinkám a některým vláknitým houbám, proti baktériím nabyla zjištěna; viz tabulka 2.Antibiotic activity is pronounced against yeast and some filamentous fungi, has been found against bacteria; see Table 2.
Tabulka 1Table 1
C NMR spektrum flavovirinu (50,31 MHz, v haxadautarodimathylaulfoxidu)C NMR Spectrum of Flavovirin (50.31 MHz, in haxadautarodimathylaulfoxide)
a; b Přiřazeni signálů označených stejným písmenem může být zaměněnoand; b Assigning signals marked with the same letter may be confused
CS 274 177 BlCS 274 177 Bl
Tabulka 2Table 2
Biologické spektrum flavovirinu a jeho srovnáni s myriocinemBiological spectrum of flavovirin and its comparison with myriocin
§ MIC - minimální inhibiční koncentrace§ MIC - minimum inhibitory concentration
Testy byly prováděny plotnovou difusni metodou.The tests were performed by the plate diffusion method.
Způsob přípravy antibiotikaMethod of preparation of an antibiotic
Produkčním organismem je kmen houby Melanconis flavovirens uložený ve sbírce CCF pod č. 1886 (autorské osvědčeni č. 234 407). Kultura je uchovávána na šikmém sladinovém agaru při teplotě 4 °C; přeočkovávána po 6 měsících. Dále jsou uvedeny příklady výroby kyseliny (flavovirinu) podle vynálezu.The production organism is a strain of Melanconis flavovirens deposited in the CCF collection under No. 1886 (Author's Certificate No. 234 407). The culture is stored on sloping wort agar at 4 ° C; revaccinated after 6 months. The following are examples of the production of an acid (flavovirin) according to the invention.
Přiklad 1Example 1
Fermentace flavovirinu probíhá bu3 v baňkách na třepačce; nebo ve fermentačnim tanku při použiti půdy o složení: glukosa 3 % hmot., kukuřičná máčecí voda (50 % hmot. sušiny) 1,5 % hmot., MgSO^.7 H^O 0,15 % hmot., pH 5,5 (upraveno KOH před aterilizaci), optimální teplota kultivace 24 °C. Inokulum je 5 % obj. submerzni kultury. Maximum produkce je mezi 12 až 14. dnem kultivace, kdy kultura obsahuje 20 až 35 mg flavovirinu v 1 L,Flavovirin fermentation occurs either in shake flasks; or in a fermentation tank using soil having the following composition: glucose 3% by weight, maize steeping water (50% by weight of dry matter) 1.5% by weight, MgSO 4 .7H 4 O 0.15% by weight, pH 5, 5 (KOH adjusted before atherilization), optimal culture temperature 24 ° C. The inoculum is 5% by volume of submerged culture. The maximum production is between 12 and 14 days of cultivation, when the culture contains 20 to 35 mg of flavovirin in 1 L,
Narostlá submerzni kultura se filtrací rozdělí na médium a mycelium. Mycelium se extrahuje methanolem. Zahuštěný methanolický extrakt se spoji s médiem a js dále čištěn chromatograficky na sloupci amberlitu XAD 2 (směs voda, methanol, až do 80 % obj. konc. methanolu). Aktivní frakce po odpařeni methanolu je extrahována chloroformem. Po odpařeCS 274 177 Dl ni chloroformu je vzorek čištěn chromatograficky na sloupci s polyamidem (směs voda : ethanol, až do 96 % obj. konc. ethanolu). Následuje adsorpčni chromatografie na sloupci silikagelu (směs chloroformmathanol, až do 80 % obj. konc. methanolu).The grown submerged culture is separated into medium and mycelium by filtration. The mycelium is extracted with methanol. The concentrated methanolic extract was combined with the medium and further purified by chromatography on an amberlite XAD 2 column (water, methanol, up to 80% v / v conc. Methanol). The active fraction after evaporation of methanol is extracted with chloroform. After evaporation of the chloroform, the sample is purified by chromatography on a polyamide column (water: ethanol, up to 96% by volume of conc. Ethanol). Adsorption chromatography on a silica gel column (chloroform / methanol up to 80% v / v methanol) follows.
Vzhledem k tomu, že antibiotický komplex kromě flavovirinu obsahuje také antibiotikum myriocln (thermozymocidin) (Aragozzini F. a kol., Tetrahedron 28: 5493, 1972, US patent 3 758 529j Begli 3. F. a kol.,' 3. Org. Chám. 38: 1253, 1973), ja nutno obě sloučeniny rozdělit. Flavovirin se za směsi izoluje jednak precipitaci v ethylacetátu, jednak chromatografii na silikagelu (soustava ieopropanol : HCOOH : HgO,’ v poměru 97 : 1,5:Since the antibiotic complex contains, in addition to flavovirin, also the antibiotic myriocin (thermozymocidin) (Aragozzini F. et al., Tetrahedron 28: 5493, 1972, U.S. Pat. No. 3,758,529, Begli 3. F. et al., 3. Org. 38: 1253 (1973), both compounds need to be separated. Flavovirin is isolated from the mixture by precipitation in ethyl acetate and by chromatography on silica gel (ieopropanol: HCOOH: HgO, 97: 1.5):
: 1,5) a analytické čistoty Ja dosaženo opakovanou krystalizaci ze směsi ethanol : voda (8:2).: 1.5) and analytical purity is achieved by repeated crystallization from ethanol: water (8: 2).
Přiklad 2Example 2
Fermentace probíhala 9tejně jako v přikladu 1. Narostlá 9ubmerzni kultura byla homogenizována s dvojnásobným objemem n-butanolu. Po odděláni mycelia filtraci se butanolické fáze odpaří a odparek je dále zpracován roztřepávánim mezi chloroformem a vodou. Dalěi postup Je shodný jako v přikladu 1.The fermentation proceeded as in Example 1. The grown 9-well culture was homogenized with twice the volume of n-butanol. After separating the mycelium by filtration, the butanolic phases are evaporated and the residue is further processed by shaking between chloroform and water. The procedure is the same as in Example 1.
Srovnáni flavovirinu 8 myrlocinam (thermozymocidinem)Comparison of flavovirin 8 myrlocinam (thermozymocidin)
Vzhledem k tomu, ža flavovirin je etrukturou blizký myriocinu (tharmozymocidinu), byla obě antibiotika porovnána Jak z hlediska fyzikálně-chemických vlastnosti;' tak z hlediska biologické aktivity.Since flavovirin is a close myriocin (tharmozymocidin) structure, both antibiotics have been compared in terms of physicochemical properties; in terms of biological activity.
Prvý rozdíl ja v produkčních organismech. Myriocin je produkován tarmofllni houbou Myriococcum albomycez Cooney a Emerson, což Js synonymum pro Thiolavia albomycos (Coonay a Emerson) Malloch a Caln, produkční kultura ja uložena va sbírce NRRL pod č. 3 858. Totéž antibiotikum bylo pod názvem thermozymocidin izolováno z blíže neurčené termofilní houby; která je uložena va sbirca ATCC pod č. 20 349. Naproti tomu produkční organismus Melanconia flavovirena (Otth) Wahm. patři do skupiny hub Pyrenomycates a vedle myriocinu (thermozymocidinu) produkuje dalši antibiotikum flavovirin.The first difference is in production organisms. Myriocin is produced by the tarmophilic fungus Myriococcum albomycez Cooney and Emerson, which is a synonym for Thiolavia albomycos (Coonay and Emerson) Malloch and Caln, a production culture deposited in the NRRL Collection under No. 3,858. mushrooms; which is deposited in the ATCC under No. 20 349. By contrast, the production organism Melanconia flavovirena (Otth) Wahm. it belongs to the group of fungi Pyrenomycates and in addition to myriocin (thermozymocidin) it produces another antibiotic flavovirin.
Rozdíl fyzikálně-chemických charakteristik mezi flavovirinam a myrlocinam ja zřejmý z tabulky č. 3. Chemická příbuznosti flavovirinu s myriocinem bylo využito při řešeni struk tury flavovirinu vzhledem ke známé absolutní kofiguraci myriocinu.The difference in physicochemical characteristics between flavovirinam and myrlocinam is evident from Table 3. The chemical affinity of flavovirin with myriocin was used to address the flavovirin structure due to the known absolute co-configuration of myriocin.
Tabulka 3Table 3
Srovnáni některých fyzikálně-chemických charakteristik flavovirinu a myriocinu (thermozymocidinu)Comparison of some physicochemical characteristics of flavovirin and myriocin (thermozymocidin)
CS 274 177 BlCS 274 177 Bl
Dalši rozdíl mezi oběma látkami je v biologické účinnosti. Při použiti difuení plotnové metody je účinek flavovirinu ve srovnáni s myriocinem ve většině připadů vyšši až 15x u druhu Pichia fermentans,' viz tabulka 2. Odpovidajici rozdíly byly zjištěny i pomoci zkumavkové zřeňovaci metody, již byly porovnávány minimální inhibiční koncentrace (MIC) a minimální fungicidni koncentrace (MFC) proti vybraným druhům kvasinek, viz tabulka 4,Another difference between the two is in biological activity. When using the plate diffusion method, the effect of flavovirin compared to myriocin in most cases is up to 15 times higher in Pichia fermentans, see Table 2. Corresponding differences were also found using the tube dilution method, comparing the minimum inhibitory concentrations (MIC) and minimal fungicidal concentration (MFC) against selected yeast species, see Table 4,
Tabulka 4Table 4
Srovnáni minimálních inhibičnich koncentraci (MIC) a minimálních fungicidnich koncentraci (MFC) flavovirinu a myriocinu na vybrané druhy kvasinek^Comparison of minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) of flavovirin and myriocin on selected yeast species ^
§ Testy byly prováděny zkumavkovou zřsňovaci metodou§ Tests were performed using the tube scaling method
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS150288A CS274177B1 (en) | 1988-03-09 | 1988-03-09 | 2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS150288A CS274177B1 (en) | 1988-03-09 | 1988-03-09 | 2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CS150288A1 CS150288A1 (en) | 1990-09-12 |
CS274177B1 true CS274177B1 (en) | 1991-04-11 |
Family
ID=5349581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS150288A CS274177B1 (en) | 1988-03-09 | 1988-03-09 | 2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS274177B1 (en) |
-
1988
- 1988-03-09 CS CS150288A patent/CS274177B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CS150288A1 (en) | 1990-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MIZUNO et al. | Studies on aculeacin i isolation and characterization of aculeacin A | |
Kluepfel et al. | Myriocin, a new antifungal antibiotic from Myriococcum albomyces | |
JPH05502163A (en) | new product | |
PT95876A (en) | PROCESS FOR THE PREPARATION OF NEW POLIPEPTIDOS | |
PT726902E (en) | POLYCYCLICAL AGENTS ANTIPARASITARIAN ITS PROCESSES AND PREPARATION AND USES OF PREPARATION AND USE | |
Nakayama et al. | Antimycin A: isolation from a new Streptomyces and activity against rice plant blast fungi | |
JPH06505150A (en) | 3-desmethylrapamycin or its derivatives, their preparation and their use as antifungal and immunosuppressive agents | |
Ishibashi | Studies on antibiotics from Helminthosporium sp. fungi. VII Siccanin, a new antifungal antibiotic produced by Helminthosporium siccans | |
Enyi et al. | Secondary metabolites from endophytic fungi of Moringa oleifera: Antimicrobial and antioxidant properties | |
EP0371509A2 (en) | Antibiotics and process for producing them | |
HU179463B (en) | Process for preparing deoxy-narasin antibiotic complex | |
CN103408550A (en) | 2,5-diketopiperazine dipeptide derived from lysobacter enzymogenes as well as preparation method and application thereof | |
CN113773355B (en) | Polyene macrolide compound and preparation method and application thereof | |
FR1465395A (en) | New compound, decoyinine and its manufacturing process | |
CS274177B1 (en) | 2-amino-2-hydroxymethyl-3,4-trans-epoxy-14-oxo-6-trans-eikosenic acid and method of its preparation | |
WO1994010843A1 (en) | Rapamycin derivatives | |
CN111011388B (en) | Application of a kind of dimethyl penicillin in anti-phytopathogenic fungi | |
FI82878B (en) | FUNGISTATISK FOERFARANDE. | |
US5840927A (en) | Sesquiterpene compounds | |
WO1994012655A1 (en) | Process for producing rapamycin derivatives | |
EP0272668B1 (en) | Amycin and its derivatives, process for their production and their use | |
US5397570A (en) | Antibiotics AB-023 and process for preparing them | |
JP2764759B2 (en) | Novel substance BT-38 substance, method for producing the same and antifungal agent containing the same as an active ingredient | |
US5086045A (en) | Antitumor antibiotic | |
EP0026485B1 (en) | Herbicoline, process for its preparation and compositions containing it |